When: Thursday, March 7, 2024 12:00 pm -1:15 pm EST
Trial #1: OCOG-2022-ROSALIE: Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy https://clinicaltrials.gov/study/NCT05866458
Speaker: Dr. Elena Parvez, MD, Assistant Professor, Department of Surgery, McMaster University; Surgical Oncologist at the Juravinski Hospital and Cancer Centre (JHCC)
Trial #2: (COG) ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy https://clinicaltrials.gov/study/NCT05602194
Speaker: Dr. Sarah Alexander, MD, Professor, Department of Paediatrics, University of Toronto; Clinical Director in the Division of Haematology/Oncology at The Hospital for Sick Children (SickKids)
Trial #3: (CCTG) HD.12 / RADAR: A Randomized Phase III Trial with a PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Previously Untreated Stage IA/IIA Hodgkin Lymphoma (RADAR) https://clinicaltrials.gov/study/NCT04685616
Speaker: Dr. Michael Crump, MD, Professor, Department of Medicine, University of Toronto; Clinical Investigator at Princess Margaret Cancer Centre; Hematologist in the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre
Tags:
Posted on: